Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | STS | P08842 | 7/20 | 0.78 |
| ▸ | ESR1 | P03372 | 3/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | CA1 | P00915 | 2/20 | 0.76 |
| ▸ | CA2 | P00918 | 2/20 | 0.76 |
| ▸ | CA9 | Q16790 | 2/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.76 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.76 |
| ▸ | CA4 | P22748 | 1/20 | 0.76 |
| ▸ | CA6 | P23280 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308964 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL12441050 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5017878 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5682139 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL959954 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10079402 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5677806 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL18658723 | 1.00 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| Ethylene SCHEMBL11570544 | 0.98 | HSD17B1 (0.95) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL3872024 | 0.93 | HSD17B1 (0.87) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2625190-B1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC, ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | UNIV JUSTUS LIEBIG GIESSEN (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-2734536-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | DONESTA BIOSCIENCE B V (NL) | 2016-09-28 | — | — | EP | disclosed |
| US-9382288-B2 | Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| EP-2348030-B1 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8987484-B2 | Process for the production of estetrol | ESTETRA S.P.R.L. (BE) | 2015-03-24 | — | — | US | disclosed |
| US-20140243539-A1 | Process for the Production of Estetrol | ESTETRA S.P.R.L. (BE) | 2014-08-28 | — | — | US | disclosed |
| US-20140235882-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | Pantarhei Biocience B.V. | 2014-08-21 | — | — | US | disclosed |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-04-17 | — | — | US | disclosed |
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NORTHEASTERN UNIVERSITY | 2008-07-10 | — | — | US | disclosed |
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NORTHEASTERN UNIVERSITY | 2008-07-10 | — | — | US | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| US-5373095-A | Steroid compounds | THE UPJOHN COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5334712-A | Estrane or androstane pyridinyl alkyl or alkylphenyl amine steroids for antidiabetes and obesity | THE UPJOHN COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| US-5274089-A | A estra-1,3,5(10)-triene derivative | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5196542-A | Phospholipase A2 inhibitors | THE UPJOHN COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-5187299-A | Phospholipase inhibitors; treating diabetes, obesity | THE UPJOHN COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5145874-A | Phospholipase inhibitor, hypoglycemic agent, antidiabetic, obesity | THE UPJOHN COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| US-4917826-A | TREATING DIABETES AND OBESITY | THE UPJOHN COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021624-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | HSD17B1 6/4885LMNA 4525/4885MAPT 4645/4885 |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | CYP19A1, HSD17B11, CYP17A1 | HSD17B1 15/4885LMNA 275/4885MAPT 4369/4885 |
| US-20140243539-A1 | Process for the Production of Estetrol | VKORC1L1, CYP46A1, DHCR7 | HSD17B1 15/4885LMNA 1969/4885MAPT 965/4885 |
| US-20140235882-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CYP19A1, HSD17B11, SULT1A1 | HSD17B1 14/4885LMNA 1578/4885MAPT 2973/4885 |
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NR5A1, SHBG, AR | HSD17B1 27/4885LMNA 3879/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.